18F-labelling of a potent nonpeptide CCR1 antagonist:: synthesis of 1-(5-chloro-2-{2-[(2R)-4-(4-[18F]fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea in an automated module

The synthesis of 1-(5-chloro-2-{2-[(2R)-4-(4-[F-18]fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea ([F-18]4), a potent nonpeptide CCR1 antagonist, is described as a module-assisted two-step one-pot procedure. The final product was obtained utilizing the reductive amination of the formed 4[F-18]fluorobenzaldehyde (2) with a piperazine derivative 3 and sodium cyanoborohydride. After HPLC purification of the final product [F-18]4, its solid phase extraction, formulation and sterile filtration, the isolated (not decay-corrected) radiochemical yields of [F-18]4 were between 7 and 13% (n = 28). The time of the entire manufacturing process did not exceed 95 min. The radiochemical purity of [F-18]4 was higher than 95%, the chemical purity >= 60% and the enantiomeric purity > 99.5%. The specific radioactivity was in the range of 59-226GBq/mu mol at starting radioactivities of 23.6-65.0GBq [F-18]fluoride. Copyright (c) 2006 John Wiley & Sons, Ltd.